TRCT
EVMN

Tower Research Capital (TRC)’s Evommune Inc EVMN Stock Holding History

Tower Research Capital (TRC)’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.7K Sell
2,249
-496
-18% -$11.2K ﹤0.01% 2713
2025
Q4 		$47K Buy
+2,745
New +$51.6K ﹤0.01% 2467

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Tower Research Capital (TRC)'s EVMN Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Evommune Inc (EVMN) stake by 18% in Q1 2026, selling an estimated $11.2K and leaving 2,249 shares worth $51.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2713.

Tower Research Capital (TRC) first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • Tower Research Capital (TRC) held 2,249 shares of Evommune Inc worth $51.7K as of Q1 2026.
  • Tower Research Capital (TRC) sold 496 Evommune Inc shares in Q1 2026, an estimated $11.2K.
  • Evommune Inc made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2713 holding.
  • Tower Research Capital (TRC) first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.